Page last updated: 2024-11-11

1,3-diolein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-diolein: RN refers to (cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3-dioleoylglycerol : A 1,3-diglyceride with both acyl groups specified as oleoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5497165
CHEMBL ID4126969
CHEBI ID75735
SCHEMBL ID3189369
MeSH IDM0237239

Synonyms (49)

Synonym
glycerol 1,3-dioleate
olein, 1,3-di- (7ci,8ci)
1,3-diolein
1,3-dioleoylglycerol
9-octadecenoic acid, 2-hydroxy-1,3-propanediyl ester, (9z,9'z)-
2465-32-9
(z,z)-1,3-dioctadecenoyl glycerol
9-octadecenoic acid (z)-, 2-hydroxy-1,3-propanediyl ester
2-hydroxy-1,3-propanediyl dioleate
9-octadecenoic acid (9z)-, 2-hydroxy-1,3-propanediyl ester (9ci)
sn-1,3-dioleoylglycerol
1,3-diolein, >=99% (gc)
dg(18:1/0:0/18:1)
257044F5-73E6-431D-83A8-070E3E0E7835
[2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate
dag(18:1/0:0/18:1)
dg(18:1(omega-9)/0:0/18:1(omega-9))
diacylglycerol(18:1/0:0/18:1)
diacylglycerol(18:1omega9/0:0/18:1omega9)
dag(18:1omega9/0:0/18:1omega9)
1,3-di-(9z-octadecenoyl)-glycerol
CHEBI:75735
dg(18:1omega9/0:0/18:1omega9)
2-hydroxypropane-1,3-diyl (9z,9'z)bis-octadec-9-enoate
erf7s0xx7k ,
einecs 219-569-3
unii-erf7s0xx7k
glyceryl 1,3-dioleate
olein, 1,3-di-
1,3-glyceryl dioleate
9-octadecenoic acid (9z)-, 2-hydroxy-1,3-propanediyl ester
SCHEMBL3189369
1,3-o-dioleoylglycerol
DRAWQKGUORNASA-CLFAGFIQSA-N
AKOS024438285
J-015618
1-(9z-octadecenoyl)-3-(9z-octadecenoyl)-sn-glycerol
1-oleoyl-3-oleoyl-sn-glycerol
dag(18:1n9/0:0/18:1n9)
dg(18:1w9/0:0/18:1w9)
diacylglycerol(18:1w9/0:0/18:1w9)
dag(18:1w9/0:0/18:1w9)
diacylglycerol(18:1n9/0:0/18:1n9)
dg(18:1n9/0:0/18:1n9)
Q27145509
CHEMBL4126969
DTXSID901030990
AS-83526
2-hydroxypropane-1,3-diyl dioleate

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Compared with the results of our previous single factor experiment, although the values of diolein yield and 1,3-diolien/diolein could not be improved markedly, the enzyme dosage and the reaction medium were spared by 25% and 20%, respectively, which was a remarkable improvement of the enzymatic process."( Rational synthesis of 1,3-diolein by enzymatic esterification.
Du, W; Duan, ZQ; Liu, DH, 2012
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
1,3-diglyceride
dioleoylglycerolA diglyceride in which both groups are oleoyl with their positions of acylation unspecified. Formula C39H72O5. For the structure shown, either R1 = H and R2 = oleoyl or R1 = oleoyl and R2 = H.
diacylglycerol (18:1/0:0/18:1)A 1,3-diglyceride in which both acyl groups contain 18 carbons and 1 double bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1491062Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Inflammation Modulatory Phorbol Esters from the Seeds of Aquilaria malaccensis.
AID1491057Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLF/CB-induced superoxide anion generation preincubated for 5 mins followed by CB stimulation for 3 mins and subsequent fMLF stimulation for 10 mins by spectrophotometric method2017Journal of natural products, 05-26, Volume: 80, Issue:5
Inflammation Modulatory Phorbol Esters from the Seeds of Aquilaria malaccensis.
AID1491063Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Inflammation Modulatory Phorbol Esters from the Seeds of Aquilaria malaccensis.
AID1491056Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay2017Journal of natural products, 05-26, Volume: 80, Issue:5
Inflammation Modulatory Phorbol Esters from the Seeds of Aquilaria malaccensis.
AID1491058Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLF/CB-induced elastase release by measuring degranulation of azurophilic granules using MeOSuc-Ala-Ala-ProVal-p-nitroanilide as substrate preincubated for 5 mins followed by CB/fM2017Journal of natural products, 05-26, Volume: 80, Issue:5
Inflammation Modulatory Phorbol Esters from the Seeds of Aquilaria malaccensis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's0 (0.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.55 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]